AGP
RARE icon

Artia Global Partners’s Ultragenyx Pharmaceutical RARE Stock Holding History

Artia Global Partners’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-150,000
Closed -$4.51M – 67
2025
Q3 		$4.51M Buy
+150,000
New +$4.5M 0.72% 22

Other funds holding RARE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Artia Global Partners's RARE Position: Q4 2025 in Review

Artia Global Partners sold out of Ultragenyx Pharmaceutical (RARE) in Q4 2025, closing a stake of 64,502 shares — an estimated $1.94M sold.

Artia Global Partners first reported a position in RARE in Q2 2025 and held it in 2 quarters. The position peaked at $1.94M in Q3 2025. 287 funds tracked by Wall St. Rank hold RARE as of Q4 2025.

  • Artia Global Partners reported no remaining Ultragenyx Pharmaceutical position as of Q4 2025 after selling out during the quarter.
  • Artia Global Partners sold 64,502 Ultragenyx Pharmaceutical shares in Q4 2025, an estimated $1.94M.
  • Artia Global Partners first reported a position in Ultragenyx Pharmaceutical in Q2 2025 and held it in 2 quarters.
  • Artia Global Partners's Ultragenyx Pharmaceutical position peaked at $1.94M in Q3 2025.
  • 287 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q4 2025.

Based on Artia Global Partners's 13F filing for Q4 2025, filed 17 Feb 2026.